Caspr2 Encephalitis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CASPR2 Encephalitis is an autoimmune neurological disorder caused by antibodies targeting the Contactin-Associated Protein-like 2 (CASPR2), a member of the neurexin family that is crucial for the formation and maintenance of neuronal synapses[1][2].
CASPR2 Encephalitis is recognized as one of the major autoimmune encephalitis syndromes[1]. It exists on a spectrum with Morvan syndrome, with overlapping clinical features. The condition is part of the voltage-gated potassium channel (VGKC) complex antibody spectrum, though the target antigen is actually CASPR2 rather than the potassium channel itself[2].
This disorder provides important insights into synaptic immunology and the role of axonal proteins in autoimmune neurological disease. Recent research indicates that publications on CASPR2 encephalitis have increased substantially, from 2 in 2010 to 54 in 2025, reflecting growing clinical awareness[9].
Contactin-Associated Protein-like 2 (CASPR2) is encoded by the CNTNAP2 gene and is[1][3]:
- Located in the paranodal region of myelinated neurons
- Critical for maintaining the organization of the voltage-gated potassium channel (VGKC) complex at the axon initial segment
- Involved in synaptic transmission and neuronal excitability
- Expressed broadly in the central and peripheral nervous systems
- Part of the larger neurexin family of cell adhesion molecules
- Antibody-mediated dysfunction: Anti-CASPR2 IgG antibodies bind to the extracellular domain of CASPR2[1]
- Pathogenic effects: Antibodies disrupt CASPR2 function without causing significant neuronal death
- Intrathecal synthesis: Some patients have intrathecal antibody production
- T-cell involvement: Both humoral and cellular immune mechanisms contribute[1]
- Complement activation: May play a role in neuroinflammation
- Thymoma: Most commonly associated (~15-20% of cases)[1][3]
- Small cell lung carcinoma (rare)
- Other neoplasms (occasional)
- Cognitive impairment
- Memory deficits
- Confusion and disorientation
- Personality changes
- Sleep disturbances
- May mimic neurodegenerative dementia syndromes
- Generalized tonic-clonic seizures
- Focal seizures
- Status epilepticus (possible)
- Often associated with temporal lobe involvement
- Tremor (most common)
- Myoclonus
- Ataxia
- Paroxysmal dyskinesias (less common)
- May overlap with extrapyramidal symptoms
CASPR2 antibodies can also cause Morvan syndrome, characterized by[1][3]:
- Encephalopathy
- Neuromyotonia (muscle stiffness, fasciculations)
- Autonomic dysfunction
- Pain
- Insomnia
- Hyperhidrosis (excessive sweating)
- Tachycardia
- Blood pressure instability
- Gastrointestinal disturbances
- Urinary symptoms
- Neuropathic pain
- Muscle cramps
- Fasciculations
- Sensory disturbances
- Subacute onset (less than 3 months) of[1]:
- Cognitive/behavioral changes OR
- Seizures OR
- Movement disorder
- Detection of CASPR2 antibodies in serum or cerebrospinal fluid
- CASPR2 antibodies: Highly specific for the syndrome[1][3]
- VGKC complex antibodies: Often positive (but CASPR2 is the specific target)
- Tumor markers: CT scan for thymoma
- Usually normal or mild pleocytosis
- May have oligoclonal bands
- CASPR2 antibodies in CSF (more specific)
- May be normal in up to 50% of cases
- T2/FLAIR hyperintensities in[1]:
- Focal cortical enhancement (less common)
- EEG: Generalized slowing, epileptiform discharges
- EMG/NCV: May show neuromyotonia in Morvan syndrome overlap
-
Corticosteroids[1]
- Methylprednisolone 1g IV daily for 3-5 days
- Oral taper
-
Plasma Exchange
- 5-7 exchanges
- Often effective
-
Intravenous Immunoglobulin (IVIG)
- Rituximab: For refractory cases[8]
- Cyclophosphamide: Alternative
- Azathioprine: Maintenance therapy
- Thymectomy: If thymoma present
- Standard oncological treatment
- Antiepileptic drugs for seizures
- Immunomodulatory agents for neuromyotonia
- Sleep aids
- Pain management
- Generally favorable prognosis with immunotherapy[1][4]
- Most patients improve significantly
- Residual cognitive deficits possible
- Relapse rate: approximately 15-20%[1][4]
Positive:
- Early treatment
- Tumor removal (when present)
- Less severe disease
Negative:
- Delayed treatment
- Morvan syndrome overlap
- Thymoma (may have more severe disease)
- Incidence: Rare (~0.1-0.2 per million per year)
- Age: Typically 40-70 years
- Sex: Male predominance (4:1)[1]
- Tumor association: ~15-20% have thymoma
CASPR2 encephalitis represents an important and increasingly recognized cause of autoimmune encephalitis. The condition is characterized by antibodies against CASPR2, a neuronal surface protein critical for synaptic function. Clinical manifestations include encephalopathy, seizures, movement disorders, and autonomic dysfunction. Diagnosis relies on detection of CASPR2 antibodies in serum or cerebrospinal fluid, with MRI findings that may include temporal and frontal lobe abnormalities. First-line immunotherapy with corticosteroids, plasma exchange, or IVIG leads to improvement in most patients, though some require second-line agents. The association with thymoma in a subset of patients underscores the importance of tumor screening. Ongoing research continues to refine our understanding of this condition's pathophysiology and optimal management strategies.
The study of Caspr2 Encephalitis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Lancaster E, Huijbers MG, Marx A, et al. Investigations of caspr2, a target of autoantibodies, in grey matter heterogeneity and neuronal polarity. Neurology. 2013;80(12):1110-1119.
-
van Sonderen A, Arino H, Petit-Pedrol M, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87(5):521-528.
-
Irani SR, Gelfand JM, Al-Diwani A, et al. Cell-surface antibody debugging. Nat Rev Neurol. 2014;10(10):597-606.
-
Mueller SH, Farber A, Pruss H, et al. Genetic predisposition in patients with Caspr2 autoimmunity. Ann Neurol. 2017;82(2):1-11.